Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes

Clinica Chimica Acta

Volumn 391, Issue 1-2, 2008, Pages 60-67

  Li, Yalin ^a,c   Zhang, Wei ^a   Guo, Dong ^a   Zhou, Gan ^a   Zhou, Honghao ^a   Xiao, Zhousheng ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

CYP2C19; CYP3A5; Genetic polymorphisms; Ilaprazole; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; DRUG METABOLITE; ILAPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CHINA; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; SULFOXIDES;

EID: 41849120414     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.02.003     Document Type: Article

References (36)

1. Welage L.S., and Berardi R.R. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 40 (2000) 52-62 quiz 121-3
2. Welage L.S. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 23 10 Pt 2 (2003) 74S-80S
3. Dekel R., Morse C., and Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 64 (2004) 277-295
4. Kil B.J., Kim I.W., Shin C.Y., et al. Comparison of IY81149 with omeprazole in rat reflux oesophagitis. J Auton Pharmacol 20 (2000) 291-296
5. Kwon D., Chae J.B., Park C.W., et al. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung 51 (2001) 204-213
6. Kim E.J., Lee R.K., Lee S.M., and Kim D.Y. General pharmacology of IY-81149, a new proton pump inhibitor. Arzneimittelforschung 51 (2001) 51-59
7. Periclou A.P., Goldwater R., Lee S.M., et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 68 (2000) 304-311
8. Sugimoto M., Furuta T., Shirai N., et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76 (2004) 290-301
9. Miura M., Kagaya H., Tada H., et al. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol 61 (2006) 315-320
10. Ulrich K., Matthias S., and Gerhard T. CYP2C19 polymorphism and proton pump inhibitors. Pharm Toxicol 95 (2004) 2-8
11. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44 (2006) 297-302
12. Pichard L., Curi-Pedrosa R., Bonfils C., et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47 (1995) 410-418
13. Katsuki H., Hamada A., Nakamura C., Arimori K., and Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 57 (2001) 709-715
14. Kim K.A., Kim M.J., Park J.Y., et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31 (2003) 1227-1234
15. Saito M., Yasui-Furukori N., Uno T., et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59 (2005) 302-309
16. Furuta T., Shirai N., Sugimoto M., Nakamura A., and Hishida A. Hydroxylation of lansoprazole in poor metabolizers of CYP2C19. Br J Clin Pharmacol 61 (2006) 361 author reply 361-2
17. Schwab M., Klotz U., Hofmann U., et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 78 (2005) 627-634
18. Myung S.W., Min H.K., Jin C., et al. Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Arch Pharm Res. 22 (1999) 189-193
19. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 26 (2004) 192-199
20. Wojnowski L., and Kamdem L.K. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2 (2006) 171-182
21. Martinez-Jimenez C.P., Jover R., Donato M.T., Castell J.V., and Gomez-Lechon M.J. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 8 (2007) 185-194
22. Koch I., Weil R., Wolbold R., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30 (2002) 1108-1114
23. Xie H.G., Wood A.J., Kim R.B., Stein C.M., and Wilkinson G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogen 5 (2004) 243-272
24. Lee S.J., and Goldstein J.A. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenom 6 (2005) 357-371
25. Daly A.K. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45 (2006) 13-31
26. Chou F.C., Tzeng S.J., and Huang J.D. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29 (2001) 1205-1209
27. Hustert E., Haberl M., Burk O., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 (2001) 773-779
28. Huang W., Lin Y.S., McConn II D.J., et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32 (2004) 1434-1445
29. Liu C.H., Peck K., Huang J.D., et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenom 6 (2005) 731-747
30. *18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353 (2005) 187-192
31. de Morais S.M., Goldstein J.A., Xie H.G., et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58 (1995) 404-411
32. Xiao Z.S., Goldstein J.A., Xie H.G., et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281 (1997) 604-609
33. He N., and Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11 (2004) 206-212
34. Scarpignato C., Pelosini I., and Di Mario F. Acid suppression therapy: where do we go from here?. Dig Dis 24 (2006) 11-46
35. Desta Z., Zhao X., Shin J.G., and Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41 (2002) 913-958
36. Chong E., and Ensom M.H. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23 (2003) 460-471